Jesús Porta Etessam-rekin lankidetzan egindako argitalpenak (30)

2024

  1. CandeSpartan Study: Candesartan Spanish Response-prediction and Tolerability study in migraine

    Cephalalgia : an international journal of headache, Vol. 44, Núm. 4

  2. Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study

    Pain Medicine (United States), Vol. 25, Núm. 3, pp. 194-202

  3. Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti-calcitonin gene-related peptide therapies: The PREVENAC study

    European Journal of Neurology, Vol. 31, Núm. 5

  4. Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study

    Pain and Therapy, Vol. 13, Núm. 3, pp. 557-576

2023

  1. Diagnosis and treatment of trigeminal neuralgia: Consensus statement from the Spanish Society of Neurology's Headache Study Group

    Neurologia, Vol. 38, pp. S37-S52

  2. Evaluating the Impact of a Training Program in Shared Decision-Making for Neurologists Treating People with Migraine

    Neurology and Therapy, Vol. 12, Núm. 4, pp. 1319-1334

  3. Study about the Manchester Triage System subtriage in patients that visited the Emergency Department due to headache

    Neurologia, Vol. 38, Núm. 4, pp. 270-277

  4. Telemedicine in the management of patients with headache: current situation and recommendations of the Spanish Society of Neurology's Headache Study Group

    Neurologia, Vol. 38, Núm. 9, pp. 635-646

2022

  1. Adaptation and Validation of the Spanish Version of Decisional Conflict Scale in People with Migraine in Spain

    Patient Preference and Adherence, Vol. 16, pp. 3291-3302

  2. Calcitonin gene–related peptide in migraine: from pathophysiology to treatment

    Neurologia, Vol. 37, Núm. 5, pp. 390-402

  3. Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients

    Cephalalgia, Vol. 42, Núm. 8, pp. 804-809

  4. Sensitivity of the SNNOOP10 list in the high-risk secondary headache detection

    Cephalalgia, Vol. 42, Núm. 14, pp. 1521-1531

2021

  1. 1st Post-European Headache Federation Meeting: A review of the latest developments presented at the 2020 European Headache Federation Congress

    Revista de Neurologia

  2. Document of revision and updating of medication overuse headache (MOH)

    Neurologia, Vol. 36, Núm. 3, pp. 229-240

  3. Failure to monoclonal antibodies against CGRP or its receptor does not preclude lack of efficacy to other drugs from the same therapeutic class

    Neurologia

  4. Management of thunderclap headache in the emergency room: A retrospective cohort study

    Cephalalgia, Vol. 41, Núm. 6, pp. 711-720

  5. Temporal distribution of emergency room visits in patients with migraine and other headaches

    Expert Review of Neurotherapeutics, Vol. 21, Núm. 5, pp. 599-605

2020

  1. Deep Phenotyping of Headache in Hospitalized COVID-19 Patients via Principal Component Analysis

    Frontiers in Neurology, Vol. 11

  2. Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine

    Neurologia, Vol. 35, Núm. 8, pp. 568-578

  3. Frequency and Type of Red Flags in Patients With Covid-19 and Headache: A Series of 104 Hospitalized Patients

    Headache, Vol. 60, Núm. 8, pp. 1664-1672